FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. USO
6. TSLA
7. AMD
8. META
9. AMC
10. COHR

Go back to FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
(NASDAQ: ARQT) Delayed: 25.96 +0.58 (2.29%)
Previous Close $25.38    52 Week High $ 
Open $25.57    52 Week Low $ 
Day High $26.08    P/E N/A 
Day Low $25.19    EPS $ 
Volume 1,888,258       

(NASDAQ: ARQT) Delayed: 25.96 +0.58 (2.29%)
Previous Close $25.38    52 Week High $ 
Open $25.57    52 Week Low $ 
Day High $26.08    P/E N/A 
Day Low $25.19    EPS $ 
Volume 1,888,258